Lenalidomide for Myelodysplastic Syndromes - Dose, Pharmacology, Side-Effects, and Contraindications

Overview:

Lenalidomide has been licensed by the United States Food and Drug Administration (FDA) for the treatment of individuals with transfusion-dependent anemia (less hemoglobin) resulting from low or intermediate-risk myelodysplastic syndromes (a class of bone marrow disorders that impact the generation of red blood cells). A diverse category of clonal myeloid neoplasms known as myelodysplastic syndromes (MDS) is defined by inadequate hematopoiesis, which results in blood cytopenias and a fluctuating risk of developing acute myeloid leukemia (AML). While Azacitidine, a hypomethylating agent, has been demonstrated to extend survival in patients with higher risk (HR)-MDS as compared to standard therapy, no medication has been proven to do the same for patients with lower-risk MDS (LR-MDS) or to halt the development of AML. In this subset of patients, Lenalidomide results in high rates of transfusion independence and cytogenetic responses. Moreover, Lenalidomide extends responder survival and postpones AML progression.

Drug Group:

Lenalidomide is a member of the immunomodulatory agents (IMiDs) pharmacological class. These medications target and destroy aberrant cells by modulating (changing) the immune system, possibly encouraging the development of healthy cells.

Available Doses and Dosage Forms:

Lenalidomide can be taken orally in capsule form. It is available in different strengths to customize dosage according to each patient's unique requirements and state.

Strengths: 2.5 mg (milligram), five mg, 10 mg, 15 mg, 20 mg, and 25 mg capsules.

For Patients:

What Is Myelodysplastic Syndrome (MDS)?

A kind of malignancy that affects the bone marrow's blood-forming cells is called myelodysplastic syndrome (MDS). These stem cells typically develop into healthy platelets, white blood cells, and red blood cells. The stem cells in MDS develop abnormally and improperly. As a result, there are not as many healthy blood cells.

The following is an outline of how it works:

• Abnormal Stem Cells: Different types of blood cells can be produced from stem cells found in the bone marrow. These stem cells experience genetic alterations and deviance in MDS.

• Inefficient Production of Blood Cells: The aberrant stem cells cannot develop into viable blood cells. They may even push out the healthy stem cells, which would result in a low level of platelets, white blood cells, and red blood cells.

• Symptoms: Exhaustion, shortness of breath, an elevated risk of infections, or easy bleeding, depending on the kind and degree of MDS.

How Does Lenalidomide Work?

A drug used to treat various forms of MDS is Lenalidomide. Although Lenalidomide’s precise mechanism of action in MDS is still being investigated, it is thought to have the following effects:

• Suppression of Cell Formation: In the bone marrow, Lenalidomide may help inhibit the formation of aberrant blood cells.

• Immune System Modulation: It may affect the immune system's capacity to identify and eliminate aberrant cells.

• Regulation of Cell Survival: Lenalidomide could affect how long healthy and aberrant blood cells survive.

By focusing on these processes, Lenalidomide can lower the risk of problems and increase blood cell counts in MDS patients.

What Is the Dosage of Lenalidomide?

Initial Dosage: An initial dosage of ten milligrams per day is advised.

1. Low Platelet Count, or Thrombocytopenia:

• After beginning therapy, if the baseline platelet count is greater than 100,000/mcL (per microliter) within four weeks, stop the treatment if the platelet count drops to less than 50,000/mcL. When platelets return to > 50,000/mcL, resume at five mg daily.

• If the baseline platelet count is less than 100,000/mcL, stop the therapy if the platelets drop to 50 percent of the baseline. When platelets return to ≥ baseline value (if ≥ 60,000/mcL) or ≥ 30,000/mcL (if baseline < 60,000/mcL), resume at five mg daily.

• After a four-week therapy period, stop the medication if platelets drop below 30,000/mcL or if platelet transfusions are necessary. When platelets return to > 30,000/mcL (without bleeding concerns), resume at five mg daily.

2. Low White Blood Cell Count, or Neutropenia:

• After beginning therapy, if the baseline absolute neutrophil count (ANC) is greater than 1,000/mcL, stop the treatment if the neutrophil count drops to less than 750/mcL. When neutrophils return to 1,000/mcL, resume at five mg daily.

• Treat the patient if the baseline ANC is less than 1,000/mcL and the neutrophil count drops to 500/mcL. After neutrophils recover to > 500/mcL, resume at five mg daily.

• After a four-week treatment period, stop the medication if neutrophil counts drop below 500/mcL for more than seven days or if there is a fever. After neutrophils recover to > 500/mcL, resume at five mg daily.

How Effective Is Lenalidomide?

Certain blood malignancies have demonstrated efficacy when treated with Lenalidomide, specifically:

• Myelodysplastic Syndromes (MDS): Lenalidomide can enhance blood cell counts and slow the advancement of MDS subtypes that might otherwise lead to acute myeloid leukemia (AML).

It is important to realize, though, that Lenalidomide is not a treatment. Although it can help control the condition and alleviate certain symptoms, it might not be able to destroy the cancer cells.

What Are the Things to Inform the Doctor Before Taking the Drug?

1. Inform the doctor of all possible medical problems before using Lenalidomide, including:

• Liver disorders.

• Suffer from renal issues or are treated with kidney dialysis.

• Possess thyroid issues.

• Have experienced a severe skin reaction while using Thalidomide. Remember not to take Lenalidomide.

2. Lactose intolerance as Lenalidomide has lactose in it.

3. Women who are nursing a child. While on Lenalidomide therapy, do not breastfeed.

4. Severe birth abnormalities may result from Lenalidomide use. Before beginning therapy, women who are or may become pregnant should talk to their doctor about birth control choices. Men who take Lenalidomide should also be mindful of the hazards that a growing baby may face if their spouse takes lenalidomide, which might raise the risk of blood clots.

5. Inform the healthcare practitioner about all the medications used, including over-the-counter and prescription drugs, herbal supplements, and vitamins. Serious adverse effects might result from the interaction between Lenalidomide and other medications. Consult the physician before starting any new medication.

How Is Lenalidomide Administered?

Lenalidomide is administered orally and is available in capsules. This is a summary of the usual ways it is administered:

• Dosage Form: Differentially formulated capsules (2.5 mg, five mg, etc.)

• Frequency: Once a day.

• Meals: Lenalidomide can be taken with or without food.

Completely swallow the capsules with water. Do not chew, smash, or open them. The precise beginning dosage will be decided by the doctor, who may change it in response to blood cell counts and treatment response. Routine blood testing is essential to keep an eye on any side effects and blood cell counts.

What Are the Side Effects of Lenalidomide?

The most frequent side effects (>15 percent) are:

• Pyrexia (raised body temperature).

• Tiredness.

• Constipation.

• Nasopharyngitis (an episode of inflammation affecting the nasal and throat cavities).

• Arthralgia (joint pain).

• Thrombocytopenia (depleted platelet count).

• Neutropenia (depleted neutrophil count).

• Diarrhea.

• Pruritus (pus-filled rash).

• Rash.

• Cough.

• Dizziness.

• Headache.

• Muscular spasm.

• Dyspnea (shortness of breath).

• Pharyngitis (pharynx inflammation).

• Epistaxis (nose bleed).

Serious:

• Deep vein thrombosis (blood clots).

• Tumor lysis syndrome (rapid breakdown of cancer cells).

• Liver problems.

• Severe skin reactions.

• Birth defects (if pregnant).

Dietary Considerations:

Although there are no set limitations, the following advice can help to get the most out of them:

• Control Side Effects: Eat bland, easily digested meals like toast, white rice, or bananas if having nausea or diarrhea.

• Support the Immune System: To boost the immune system, eat a diet rich in fruits, vegetables, and whole grains to obtain all the vitamins and minerals needed.

• Keep Hydrated: Consume lots of liquids to promote general health and avoid constipation.

• Consumption of Fiber: Talk to the doctor. Low-fiber diets may be advised in some situations to treat diarrhea, but a balanced fiber intake may be best in others.

Missed Dose:

Lenalidomide should not be taken twice at once if a dosage is missed.

To find out how to continue, speak with the doctor. They could suggest forgoing the missing dose and going back to the usual routine the next day.

Overdose:

Regarding the treatment of Lenalidomide overdose in MDS patients, there is no particular experience. In research including dosage range in healthy participants, up to 200 mg (given 100 mg twice a day) was exposed to some people, while in studies using single doses, up to 400 mg was exposed to certain patients. The main adverse events that were documented were pruritus, urticaria, rash, and increased liver transaminases. Neutropenia and thrombocytopenia were the dose-limiting toxicities seen in clinical studies.

Storage:

• Keep Lenalidomide capsules out of direct sunlight and at room temperature, between 20 and 25 degrees Celsius.

• Keep the medication out of children's and pets' reach and in its original container.

• It is not advisable to flush away leftover medicine down the sink or toilet. Find out from the pharmacist how to dispose of materials properly.

For Doctors:

Indications:

The thalidomide analog Lenalidomide is prescribed to treat patients with the following conditions when combined with Dexamethasone:

• Multiple myeloma (MM) in individuals who have had at least one previous therapy.

• Transfusion-dependent anemia, caused by myelodysplastic syndromes (MDS) with low- or intermediate-risk, is linked to a deletion 5q abnormality alone or in conjunction with other cytogenetic abnormalities.

• Mantle cell lymphoma (MCL) patients whose illness has worsened or returned following two previous treatments, one of which includes the use of Bortezomib.

Dose:

Ten mg once a day; treatment is either kept up or changed in response to clinical and laboratory results until the condition worsens or the toxicity becomes intolerable.

Dosing Considerations:

The following are important things to keep in mind when administering Lenalidomide:

• It is important to speak with the doctor to find out the right dose for the particular circumstances.

• Never use Lenalidomide without a prescription, and make sure to closely adhere to the doctor's instructions.

• Monitoring blood counts closely is crucial throughout treatment.

• Modification of dosage may be required to control adverse effects or maximize responsiveness to therapy.

What Are the Pharmacological Aspects of Lenalidomide?

1. Pharmacodynamics:

Lenalidomide is thought to have many immunomodulatory effects on the immune system. It may:

• Prevent the development of aberrant red blood cells.

• Encourage the natural killer (NK) cells in the body to target cancerous cells.

• Control the synthesis of cytokines, which are immune response-related chemical messengers.

• Modulation of cereblon: Lenalidomide attaches itself to the cereblon protein. Certain cellular proteins necessary for the development and survival of cancer cells are degraded due to this complex formation.

2. Mechanism:

Lenalidomide acts on MDS cells directly as well as indirectly on the immune system while treating the condition.

Direct Results:

• Haplodeficient Genes: Lenalidomide specifically targets genes (such as 5q-) that have decreased activity in MDS as a result of deletions.

• Cell Cycle Arrest: In the G2/M phase, it inhibits phosphatase, resulting in cell cycle arrest.

• Apoptosis: In MDS cells with 5q-, it decreases CK1α (Protein in the blood) protein levels, facilitating p53-mediated cell death.

Indirect Results (Immunoregulation):

• T Cell Activation: By increasing CD28 signaling, Lenalidomide improves T cell responsiveness.

• Activation of Natural Killer Cells: It provokes natural killer cells to assault MDS cells.

• Decreased Inflammation: Lenalidomide improves the environment of the bone marrow by reducing pro-inflammatory cytokines and increasing anti-inflammatory ones.

• Anti-Angiogenesis: It inhibits the marrow's production of new blood vessels, which may delay the course of the illness.

3. Pharmacokinetics:

• Absorption: Lenalidomide is readily absorbed after oral treatment.

• Distribution: It is present all across the body except in red blood cells, where concentrations are greater.

• Metabolism: The liver is the site of significant metabolism for Lenalidomide.

• Excretion: The kidneys are primarily responsible for getting rid of Lenalidomide and its metabolites.

Toxicity:

1. Non-Clinical Toxicity

• There is no research on Lenalidomide's carcinogenicity.

• Lenalidomide did not cause chromosomal aberrations in cultured human peripheral blood lymphocytes or mutations at the thymidine kinase (tk) locus in mouse lymphoma cells. It was also not mutagenic in the bacterial reverse mutation test (Ames test).

• Lenalidomide did not cause micronuclei to develop in the polychromatic erythrocytes of the male rats' bone marrow or promote morphological transformation in the Syrian Hamster Embryo experiment.

• Lenalidomide up to 500 mg/kg (about 200 times the human dosage of 25 mg, depending on body surface area) was administered to rats in research on fertility and early embryonic development; no parental toxicity or negative effects on fertility were seen.

Clinical Toxicity:

Following are some of the potential toxicities:

Common:

• Fatigue.

• Nausea.

• Diarrhea.

• Constipation.

• Low blood cell counts (neutropenia, thrombocytopenia).

• Skin rash.

• Muscle or joint pain.

• Headache.

Serious:

• Deep vein thrombosis (blood clots).

• Tumor lysis syndrome (rapid breakdown of cancer cells).

• Liver problems.

• Severe skin reactions.

Clinical Studies:

Numerous clinical trials support the use of Lenalidomide in the treatment of MDS. The following are some salient points:

• Research has shown that in individuals with low-risk MDS, it is beneficial in raising blood counts and lowering the requirement for blood transfusions.

• Its potential in conjunction with other MDS therapies is still being investigated, as is its long-term impact.

What Are the Contraindications of Lenalidomide?

• Pregnant: If Lenalidomide is given to a pregnant woman, it may damage the fetus. Neural tube defects were seen in the progeny of monkeys administered Lenalidomide during organogenesis. This impact was observed at every tested dosage.

• Excessive Hypersensitivity Responses: Patients with severe hypersensitivity to Lenalidomide (e.g., angioedema, Stevens-Johnson syndrome, toxic epidermal necrolysis) should not use Lenalidomide.

Warnings and Precautions:

• Allergic Responses: Hypersensitivity, angioedema, Stevens-Johnson syndrome, and toxic epidermal necrolysis are examples of allergic responses that might be deadly; if such events are anticipated, stop using Lenalidomide. Do not resume Lenalidomide if these responses are verified.

• Tumor Lysis Syndrome (TLS): Patients with a high tumor burden who are at risk of TLS should be closely monitored, and necessary measures should be taken.

• Tumor Flare Reaction: Serious tumor flare responses have happened when Lenalidomide has been used experimentally for lymphoma and chronic lymphocytic leukemia.

• Hepatotoxicity: Failure of the liver, even death, can be caused. Keep a check on liver function. Put an end to Lenalidomide and assess whether hepatotoxicity is suspected.

• Secondary Primary Malignancies (SPM): Patients with multiple myeloma undergoing controlled studies that used Lenalidomide had higher occurrences of SPM.

What Are the Drug Interactions of Lenalidomide?

• Concurrent Lenalidomide medication increases the Cmax (maximum concentration) and AUC (area under the curve) in blood; periodic monitoring of Digoxin plasma levels is advised.

• Individuals undergoing concurrent treatments, such as therapy containing estrogen or erythropoietin-stimulating drugs, may be at heightened risk of developing venous thromboembolism.

Specific Considerations:

• Fertility: Male sperm production is harmed by Lenalidomide. Before beginning therapy, discuss fertility-related issues with the medical professional.

• Vaccination: Because Lenalidomide weakens the immune system, live vaccinations are often not advised at this time.

• Sun Protection: Lenalidomide may make one more sensitive to the sun. It is advised to take sun safety precautions, such as wearing protective clothes and sunscreen.

• Breastfeeding Mothers: Stop taking drugs or breastfeeding while keeping in mind how important the drug is to the mother.

• Kidney Impairment: Patients with moderate to severe renal impairment who are receiving dialysis should have their initial dose of the medication adjusted.